GlassScriptPhysician profile
Michael T Caire
NPI 1770802134
$6,978.68
in general payments reported to CMS, 2019-2025
33 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $211 · 2021: $427 · 2022: $457 · 2023: $1,276 · 2024: $2,118 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,604 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.02 |
| Education | $148.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.16 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $1,244.89 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $502.46 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $409.25 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.20 | 2020-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $343.59 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $321.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $271.77 | 2023-2025 | |
| Celgene Corporation | $246.51 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $214.03 | 2020-2025 | Ocaliva |
| Intuitive Surgical, INC. | $133.18 | 2025 | |
| Boston Scientific Corporation | $121.48 | 2019-2023 | Endoarmor |
| Evoke Pharma, INC. | $117.92 | 2024 | |
| Lilly USA, LLC | $111.67 | 2024-2025 | Omvoh |
| Axonics, INC. | $106.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $102.25 | 2024-2025 | Ibsrela |
| Palette Life Sciences, INC. | $88.95 | 2022 | |
| Ironwood Pharmaceuticals, INC | $81.91 | 2019-2024 | |
| Redhill Biopharma INC. | $79.38 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Phathom Pharmaceuticals, INC. | $61.25 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $51.90 | 2021-2023 | |
| Amgen INC. | $44.75 | 2023-2025 | Avsola, Uplizna |
| Fresenius Kabi USA, LLC | $44.68 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $41.83 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $39.82 | 2023-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $36.64 | 2024 | Dificid, Zinplava |
| Neuraxis, INC. | $33.37 | 2025 | |
| Vivus LLC | $32.90 | 2024-2025 | Pancreaze |
| Allergan, INC. | $26.97 | 2019 | |
| Celltrion USA INC. | $24.06 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $21.43 | 2024 | Zeposia |
| Pfizer INC. | $19.01 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.09 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.